Abstract
Atherosclerosis (AS), the underlying cause of most cardiovascular events, is one of the most common
causes of human morbidity and mortality worldwide due to the lack of an efficient strategy for targeted
therapy. In this work, we aimed to develop an ideal biomimetic nanoparticle for targeted AS therapy.
Methods: Based on macrophage "homing" into atherosclerotic lesions and cell membrane coating
nanotechnology, biomimetic nanoparticles (MM/RAPNPs) were fabricated with a macrophage membrane
(MM) coating on the surface of rapamycin-loaded poly (lactic-co-glycolic acid) copolymer (PLGA)
nanoparticles (RAPNPs). Subsequently, the physical properties of the MM/RAPNPs were characterized.
The biocompatibility and biological functions of MM/RAPNPs were determined in vitro. Finally, in AS
mouse models, the targeting characteristics, therapeutic efficacy and safety of the MM/RAPNPs were
examined.
Results: The advanced MM/RAPNPs demonstrated good biocompatibility. Due to the MM coating, the
nanoparticles effectively inhibited the phagocytosis by macrophages and targeted activated endothelial
cells in vitro. In addition, MM-coated nanoparticles effectively targeted and accumulated in atherosclerotic
lesions in vivo. After a 4-week treatment program, MM/RAPNPs were shown to significantly delay the
progression of AS. Furthermore, MM/RAPNPs displayed favorable safety performance after long-term
administration.
Conclusion: These results demonstrate that MM/RAPNPs could efficiently and safely inhibit the
progression of AS. These biomimetic nanoparticles may be potential drug delivery systems for safe and
effective anti-AS applications.
Anno
2021
Autori IAC
Tipo pubblicazione
Altri Autori
Yi Wang, Kang Zhang, Tianhan Li, Ali Maruf, Xian Qin, Li Luo, Yuan Zhong, Juhui Qiu, Sean McGinty, Giuseppe Pontrelli, Xiaoling Liao, Wei Wu, Guixue Wang
Editore
Ivyspring International Publisher,
Rivista
Theranostics